Stock AZN ASTRAZENECA PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials AstraZeneca PLC Nasdaq

Equities

AZN

US0463531089

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
75.17 USD +0.19% Intraday chart for AstraZeneca PLC +9.66% +11.61%
Apr. 26 ASTRAZENECA : DZ Bank sticks Neutral ZD
Apr. 26 ASTRAZENECA : UBS keeps a Sell rating ZD

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 132,331 131,461 181,878 210,243 209,128 231,480 - -
Enterprise Value (EV) 1 144,340 143,328 206,261 233,166 231,638 251,156 244,845 238,051
P/E ratio 97.9 x 41 x 1,468 x 64.3 x 35.4 x 27.2 x 22.9 x 20.3 x
Yield 2.78% 2.8% 2.44% 2.14% 2.15% 2.09% 2.18% 2.27%
Capitalization / Revenue 5.43 x 4.94 x 4.86 x 4.74 x 4.57 x 4.52 x 4.23 x 4.01 x
EV / Revenue 5.92 x 5.38 x 5.51 x 5.26 x 5.06 x 4.91 x 4.47 x 4.12 x
EV / EBITDA 21.6 x 17.2 x 27.2 x 25.2 x 17.1 x 14.1 x 12.2 x 11 x
EV / FCF 72.5 x 37.3 x 42.3 x 26.7 x 25.8 x 28 x 20.8 x 17.3 x
FCF Yield 1.38% 2.68% 2.36% 3.74% 3.88% 3.57% 4.81% 5.78%
Price to Book 10 x 8.41 x 4.24 x 5.67 x 5.38 x 5.66 x 4.84 x 4.43 x
Nbr of stocks (in thousands) 1,311,913 1,312,660 1,549,159 1,549,528 1,549,926 1,550,231 - -
Reference price 2 100.9 100.1 117.4 135.7 134.9 149.3 149.3 149.3
Announcement Date 2/14/20 2/11/21 2/10/22 2/9/23 2/8/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 24,384 26,617 37,417 44,351 45,811 51,185 54,764 57,765
EBITDA 1 6,686 8,311 7,586 9,237 13,580 17,822 20,004 21,723
EBIT 1 6,436 7,340 9,928 13,350 14,534 16,762 18,975 20,572
Operating Margin 26.39% 27.58% 26.53% 30.1% 31.73% 32.75% 34.65% 35.61%
Earnings before Tax (EBT) 1 1,548 3,916 -265 2,501 6,899 10,863 13,027 14,270
Net income 1 1,335 3,196 112 3,288 5,961 8,519 10,195 11,616
Net margin 5.47% 12.01% 0.3% 7.41% 13.01% 16.64% 18.62% 20.11%
EPS 2 1.030 2.440 0.0800 2.110 3.810 5.486 6.524 7.362
Free Cash Flow 1 1,990 3,838 4,872 8,717 8,984 8,965 11,787 13,765
FCF margin 8.16% 14.42% 13.02% 19.65% 19.61% 17.51% 21.52% 23.83%
FCF Conversion (EBITDA) 29.76% 46.18% 64.22% 94.37% 66.16% 50.3% 58.92% 63.37%
FCF Conversion (Net income) 149.06% 120.09% 4,350% 265.12% 150.71% 105.23% 115.62% 118.5%
Dividend per Share 2 2.800 2.800 2.870 2.900 2.900 3.119 3.250 3.392
Announcement Date 2/14/20 2/11/21 2/10/22 2/9/23 2/8/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2020 S2 2021 S1 2021 Q4 2021 S2 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2022 S2 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 - - - 12,011 - 11,390 10,771 - 10,982 11,207 - 10,879 11,416 11,492 12,024 12,679 12,633 12,923 13,616 12,820 13,395
EBITDA 1 - - - 1,900 - 2,187 1,896 - 2,579 2,574 - - 3,732 - - - 4,602 4,711 6,276 - -
EBIT 1 - - - 3,318 - 3,961 3,365 - 3,413 2,610 - 3,946 4,291 3,545 2,752 4,310 4,216 4,342 3,967 - -
Operating Margin - - - 27.62% - 34.78% 31.24% - 31.08% 23.29% - 36.27% 37.59% 30.85% 22.89% 33.99% 33.38% 33.6% 29.14% - -
Earnings before Tax (EBT) 1 - - - -636 - 553 247 - 922 778 - 2,262 2,088 1,652 897 2,800 2,489 2,959 3,074 - -
Net income 1 - - - -347 - 386 360 - 1,640 901 - 1,803 1,818 1,378 959 2,179 2,396 2,337 2,463 - -
Net margin - - - -2.89% - 3.39% 3.34% - 14.93% 8.04% - 16.57% 15.93% 11.99% 7.98% 17.19% 18.97% 18.08% 18.09% - -
EPS 2 - - - -0.2200 - 0.2500 0.2300 - 1.050 0.5800 - 1.160 1.170 0.8900 0.6200 1.410 1.537 1.503 1.584 - -
Dividend per Share 2 0.9000 1.900 0.9000 1.970 1.970 - 0.9300 0.9300 - 1.970 1.970 - 0.9300 - 1.970 - 0.8775 0.7750 1.422 0.8750 0.8750
Announcement Date 7/30/20 2/11/21 7/29/21 2/10/22 2/10/22 4/29/22 7/29/22 7/29/22 11/10/22 2/9/23 2/9/23 4/27/23 7/28/23 11/9/23 2/8/24 4/25/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 12,009 11,867 24,383 22,923 22,510 19,675 13,364 6,571
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.796 x 1.428 x 3.214 x 2.482 x 1.658 x 1.104 x 0.6681 x 0.3025 x
Free Cash Flow 1 1,990 3,838 4,872 8,717 8,984 8,965 11,787 13,765
ROE (net income / shareholders' equity) 35.6% 36.7% 27.5% 27.2% 29.8% 28.8% 30.3% 30.6%
ROA (Net income/ Total Assets) 2.19% 4.99% 8.77% 3.26% 11.5% 9.36% 10.6% 11.4%
Assets 1 61,015 64,053 1,277 100,924 51,935 91,041 96,275 101,688
Book Value Per Share 2 10.10 11.90 27.70 23.90 25.10 26.40 30.80 33.70
Cash Flow per Share 2 2.280 3.660 4.180 6.290 6.620 8.880 10.40 12.10
Capex 1 979 961 1,091 1,091 1,361 2,311 2,097 2,015
Capex / Sales 4.01% 3.61% 2.92% 2.46% 2.97% 4.51% 3.83% 3.49%
Announcement Date 2/14/20 2/11/21 2/10/22 2/9/23 2/8/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for AstraZeneca PLC

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
149.3 USD
Average target price
164.4 USD
Spread / Average Target
+10.08%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
PFIZER, INC. Stock Pfizer, Inc.
-11.77% 144B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. AZN Stock
  4. AZN Stock
  5. Financials AstraZeneca PLC